Join experts Drs Benjamin Schlechter and Diane Saverese as they discuss systemic therapy for advanced colorectal cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988974). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Characterization of Two Metastatic Subpopulations Originating From a Single Human Colon Carcinoma https://pubmed.ncbi.nlm.nih.gov/6861147/
The Phenomenon of Pleiotropic Drug Resistance https://pubmed.ncbi.nlm.nih.gov/3331384/
Early Memories of Burton "Bud" Rose, Founder of UpToDate — and Medical Education Visionary https://blogs.jwatch.org/hiv-id-observations/index.php/early-memories-of-burton-bud-rose-founder-of-uptodate-and-medical-education-visionary/2020/05/06/
Combining Chemotherapy and Targeted Therapies in Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/17990352/
Addition of Cetuximab to Oxaliplatin-Based First-Line Combination Chemotherapy for Treatment of Advanced Colorectal Cancer: Results of the Randomised Phase 3 MRC COIN Trial https://pubmed.ncbi.nlm.nih.gov/21641636/
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? https://pubmed.ncbi.nlm.nih.gov/28214977/
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM) https://pubmed.ncbi.nlm.nih.gov/30552157/
FOLFOXIRI Plus Bevacizumab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment of Patients With Metastatic Colorectal Cancer: Updated Overall Survival and Molecular Subgroup Analyses of the Open-Label, Phase 3 TRIBE Study https://pubmed.ncbi.nlm.nih.gov/26338525/
Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials https://pubmed.ncbi.nlm.nih.gov/23881988/
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/19339720/
Final Results From PRIME: Randomized Phase III Study of Panitumumab With FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/24718886/
FOLFIRI Plus Cetuximab or Bevacizumab for Advanced Colorectal Cancer: Final Survival and Per-Protocol Analysis of FIRE-3, A Randomised Clinical Trial https://pubmed.ncbi.nlm.nih.gov/33154570/
FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment for Patients With Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/25088940/
Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong? https://pubmed.ncbi.nlm.nih.gov/30545999/
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/34061178/
Effect of Duration of Adjuvant Chemotherapy for Patients With Stage III Colon Cancer (IDEA Collaboration): Final Results From a Prospective, Pooled Analysis of Six Randomised, Phase 3 Trials https://pubmed.ncbi.nlm.nih.gov/33271092/
Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance) https://pubmed.ncbi.nlm.nih.gov/30688523/
The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials https://pubmed.ncbi.nlm.nih.gov/31855256/
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial https://pubmed.ncbi.nlm.nih.gov/34516759/